Loading organizations...
§ Venture Capital · USA
venture capital firm investing strategic capital and hands-on support for early-stage companies in medical technologies.
Key people at BlueStone Venture Partners.
BlueStone Venture Partners is an early-stage venture capital firm based in Tucson, Arizona, that provides equity funding and operational support to emerging companies. The investment vehicle primarily targets the healthcare and medical technology sectors, structuring its capital deployment across various financing stages from initial seed rounds through advanced growth equity. Demonstrating its investment scale, the firm recently participated in a $45 million Series C equity financing round for GT Medical Technologies, a key portfolio company. The management team utilizes its combined financial and technical background to assist entrepreneurs, while its leadership maintains external advisory relationships with major global organizations, including The Rockefeller Foundation. Operating with a dedicated research staff managed by Chris Burwell, the firm evaluates complex medical technology innovations. BlueStone Venture Partners was founded by its managing directors and co-founders Tom Nickoloff and Mara Aspinall.
Key people at BlueStone Venture Partners.
BlueStone Venture Partners is a premier life sciences venture capital firm focused on early-stage investments primarily in the Southwestern United States. Their mission is to identify and nurture innovative companies in sectors such as medical devices, health IT, advanced materials, and molecular diagnostics, providing strategic capital and operational support to help entrepreneurs transform groundbreaking ideas into market-ready healthcare solutions. By leveraging deep industry expertise and a strong regional network, BlueStone plays a vital role in advancing the life sciences startup ecosystem in an undercapitalized but innovation-rich region[1][2][4].
Founded in 2017 and headquartered in Santa Fe, New Mexico, BlueStone was co-founded by Mara Aspinall and Tom Nickoloff, who bring extensive experience in venture investing and life sciences. The firm’s origin is inspired by the symbolism of turquoise, a native Southwest stone representing success and protection, reflecting their commitment to fostering innovation rooted in the region’s unique ecosystem. Over time, BlueStone has evolved to focus on seed and early-stage investments, emphasizing a hands-on, operator-first approach to support portfolio companies through growth and exit[2][4][5].
BlueStone rides the growing trend of life sciences innovation driven by advances in diagnostics, precision medicine, and health technology. The timing is favorable due to increasing healthcare demands, technological breakthroughs, and a rising focus on regional innovation ecosystems beyond traditional hubs like Silicon Valley. By channeling capital and expertise into early-stage companies in the Southwest, BlueStone helps diversify and strengthen the national life sciences landscape, fostering economic growth and healthcare advancements in an underserved region[1][2][3].
Looking ahead, BlueStone Venture Partners is well-positioned to capitalize on continued growth in life sciences innovation, particularly as healthcare technology and diagnostics evolve rapidly. Their regional focus and operator-driven model should enable them to identify and scale promising startups that might otherwise be overlooked. As the Southwest’s innovation ecosystem matures, BlueStone’s influence is likely to expand, potentially attracting more capital and catalyzing further breakthroughs in healthcare solutions[1][2][4].
In essence, BlueStone Venture Partners embodies a strategic blend of regional insight, sector expertise, and hands-on support, making it a key player in shaping the future of life sciences innovation outside traditional venture capital centers.
BlueStone Venture Partners has 6 tracked investments across 4 companies. The latest tracked deal is $23.0M Series A in Predicta Biosciences in September 2025.
